PET/CT scan to detect PD-L1 in several types of cancer
Tests a PET/CT scan showing PD-L1 in adults with cancer.
Plain-language title generated from the registry record
Registry title: Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
Key facts
- Where
- Jinan, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer or esophageal cancer. Their tumor must show PD-L1. They get a PET/CT scan with [18F]AlF-NOTA-PCP2.
- Age
- 18 years or older
- Sex
- All genders can join.
- Disease stage
- Tumor confirmed by pathology, with at least one measurable tumor lesion still present. Performance status (ECOG) of 0-1.
- Earlier treatment
- Must have recovered from side effects of earlier treatment (grade 1 or less, or back to baseline, not counting fatigue or hair loss).
- Biomarker or test result
- PD-L1 must be detectable in the tumor tissue (by immunohistochemistry or biopsy).
Main reasons for not taking part
- Taking part in another interventional clinical trial
- Pregnant or breastfeeding women
- Severe or uncontrolled heart or other body-wide disease, or a recent arterial blood clot within 6 months
- Active infection needing treatment through the whole body
- Allergy to [18F]AlF-NOTA-PCP2 or any of its ingredients
Read by machine on 9 November 2026.
Where in China
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical SciencesJinan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Man Hu
- Trial code
- NCT06690216
- Record updated
- 30 March 2025
- Original description
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer. The primary aim is to establish the correlation between [18F]AlF-NOTA-PCP2 uptake and PD-L1 expression in tumor tissues, while secondary objectives include evaluating its role in predicting clinical outcomes such as progression-free survival (PFS) and overall survival (OS). By providing a non-invasive, quantitative, and reproducible method for assessing PD-L1, this study aims to refine patient stratification and improve the precision of immunotherapy decision-making.Read full original descriptionShow less
Evaluation of the Value of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer. The primary aim is to establish the correlation between [18F]AlF-NOTA-PCP2 uptake and PD-L1 expression in tumor tissues, while secondary objectives include evaluating its role in predicting clinical outcomes such as progression-free survival (PFS) and overall survival (OS). By providing a non-invasive, quantitative, and reproducible method for assessing PD-L1, this study aims to refine patient stratification and improve the precision of immunotherapy decision-making.
Inclusion: Signed informed consent obtained; Age ≥ 18 years, any gender; Pathologically confirmed malignant tumors, including:; Glioblastoma; Head and neck squamous cell carcinoma; Non-small cell lung cancer; Esophageal cancer; Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy); Measurable disease with at least one residual tumor lesion; ECOG performance status of 0-1; No contraindications to [18F]AlF-NOTA-PCP2 PET/CT imaging; Willing and able to comply with study procedures and follow-up visits.
Exclusion: Failure to recover from toxic effects or complications of prior interventions (≤ grade 1 or baseline levels, excluding fatigue or hair loss); Any arterial thrombotic or embolic events within 6 months before enrollment (e.g., myocardial infarction, cerebrovascular accident, transient ischemic attack); Women of childbearing potential without a negative pregnancy test prior to study entry; Severe or uncontrolled systemic diseases, including:; Major, symptomatic arrhythmias or significant ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, or ventricular arrhythmias); Unstable angina or congestive heart failure (NYHA class ≥ 2); Active or uncontrolled infections requiring systemic treatment; Severe psychiatric disorders affecting study participation; Known allergy or hypersensitivity to [18F]AlF-NOTA-PCP2 or any component of the radiopharmaceutical; Any medical history, laboratory abnormality, or condition that may:; Participation in another interventional clinical trial; Pregnant or breastfeeding women; Interfere with study results; Affect patient participation; Pose an unacceptable risk as determined by the investigator.